{"doi":"10.1523/jneurosci.2860-04.2004","title":"Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention","abstract":"<jats:p>Insulin-degrading enzyme (IDE) is one of the proteins that has been demonstrated to play a key role in degrading β-amyloid (Aβ) monomer<jats:italic>in vitro</jats:italic>and<jats:italic>in vivo</jats:italic>, raising the possibility of upregulating IDE as an approach to reduce Aβ. Little is known, however, about the cellular and molecular regulation of IDE protein. Because one of the main functions of IDE is to degrade insulin, we hypothesized that there is a negative feedback mechanism whereby stimulation of insulin receptor-mediated signaling upregulates IDE to prevent chronic activation of the pathway. We show that treatment of primary hippocampal neurons with insulin increased IDE protein levels by ∼25%. Insulin treatment also led to phosphatidylinositol-3 (PI3) kinase activation evidenced by Akt phosphorylation, which was blocked by PI3 kinase inhibitors, wortmannin and LY 294002. Inhibition of PI3 kinase abolished the IDE upregulation by insulin, indicating a cause-effect relationship between insulin signaling and IDE upregulation. Further support for this link was provided by the findings that deficient insulin signaling (decreased PI3 kinase subunit P85) was correlated with reduced IDE in Alzheimer's disease (AD) brains and in Tg2576 Swedish amyloid precursor protein transgenic mice fed a safflower oil-enriched (“Bad”) diet used to accelerate pathogenesis. Consistent with IDE function in the degradation of Aβ monomer, the IDE decrease in the Bad diet-fed Tg2576 mice was associated with increased Aβ monomer levels. These<jats:italic>in vitro</jats:italic>and<jats:italic>in vivo</jats:italic>analyses validate the use of enhanced CNS insulin signaling as a potential strategy for AD intervention to correct the IDE defects occurring in AD.</jats:p>","journal":"The Journal of Neuroscience","year":2004,"id":682210,"datarank":0.8684940256345881,"base_score":5.7899601708972535,"endowment":5.7899601708972535,"self_citation_contribution":0.8684940256345881,"citation_network_contribution":0.0,"self_endowment_contribution":0.8684940256345881,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":326,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":632901,"name":"Bruce Teter","orcid":"0000-0002-8337-4491","position":1,"is_corresponding":false},{"id":146946,"name":"Takashi Morihara","orcid":null,"position":2,"is_corresponding":false},{"id":1782278,"name":"Giselle P. Lim","orcid":null,"position":3,"is_corresponding":false},{"id":1782279,"name":"Surendra S. Ambegaokar","orcid":null,"position":4,"is_corresponding":false},{"id":1782280,"name":"Oliver J. Ubeda","orcid":null,"position":5,"is_corresponding":false},{"id":344634,"name":"Sally A. Frautschy","orcid":"0000-0003-0194-0363","position":6,"is_corresponding":false},{"id":178505,"name":"Greg M. Cole","orcid":null,"position":7,"is_corresponding":false},{"id":385981,"name":"Lixia Zhao","orcid":"0000-0002-9217-5398","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention","abstract":"<jats:p>Insulin-degrading enzyme (IDE) is one of the proteins that has been demonstrated to play a key role in degrading β-amyloid (Aβ) monomer<jats:italic>in vitro</jats:italic>and<jats:italic>in vivo</jats:italic>, raising the possibility of upregulating IDE as an approach to reduce Aβ. Little is known, however, about the cellular and molecular regulation of IDE protein. Because one of the main functions of IDE is to degrade insulin, we hypothesized that there is a negative feedback mechanism whereby stimulation of insulin receptor-mediated signaling upregulates IDE to prevent chronic activation of the pathway. We show that treatment of primary hippocampal neurons with insulin increased IDE protein levels by ∼25%. Insulin treatment also led to phosphatidylinositol-3 (PI3) kinase activation evidenced by Akt phosphorylation, which was blocked by PI3 kinase inhibitors, wortmannin and LY 294002. Inhibition of PI3 kinase abolished the IDE upregulation by insulin, indicating a cause-effect relationship between insulin signaling and IDE upregulation. Further support for this link was provided by the findings that deficient insulin signaling (decreased PI3 kinase subunit P85) was correlated with reduced IDE in Alzheimer's disease (AD) brains and in Tg2576 Swedish amyloid precursor protein transgenic mice fed a safflower oil-enriched (“Bad”) diet used to accelerate pathogenesis. Consistent with IDE function in the degradation of Aβ monomer, the IDE decrease in the Bad diet-fed Tg2576 mice was associated with increased Aβ monomer levels. These<jats:italic>in vitro</jats:italic>and<jats:italic>in vivo</jats:italic>analyses validate the use of enhanced CNS insulin signaling as a potential strategy for AD intervention to correct the IDE defects occurring in AD.</jats:p>","is_dataset_classified":null,"base_score":5.7899601708972535,"endowment":5.7899601708972535,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"15590928","pmcid":"PMC6730264","openalex_id":"https://openalex.org/W2146405340","authors":[],"funders":[{"funder_name":"NIA NIH HHS","grant_id":"P50 AG016570","title":null},{"funder_name":"NCCIH NIH HHS","grant_id":"R01 AT003008","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P50 AG005142","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P50 AG16570","title":null},{"funder_name":"NIA NIH HHS","grant_id":"R01 AG13471","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P50 AG05142","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U01 CA091343","title":null},{"funder_name":"NIA NIH HHS","grant_id":"R01 AG16793","title":null},{"funder_name":"NIA NIH HHS","grant_id":"R01 AG016793","title":null}],"total_grants":9,"fwci":5.9653,"citation_percentile":0.9704682,"influential_citations":0,"citation_trend":[{"year":2012,"count":14},{"year":2013,"count":10},{"year":2014,"count":19},{"year":2015,"count":12},{"year":2016,"count":16},{"year":2017,"count":22},{"year":2018,"count":15},{"year":2019,"count":19},{"year":2020,"count":11},{"year":2021,"count":14},{"year":2022,"count":20},{"year":2023,"count":10},{"year":2024,"count":15},{"year":2025,"count":11},{"year":2026,"count":3}],"oa_status":"bronze","license":"https://creativecommons.org/licenses/by-nc-sa/4.0/","oa_locations":[{"url":"https://www.jneurosci.org/content/jneuro/24/49/11120.full.pdf","host_type":"journal"},{"url":"https://www.jneurosci.org/content/jneuro/24/49/11120.full.pdf","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1523/JNEUROSCI.2860-04.2004","host_type":"publisher"},{"url":"https://doi.org/10.1523/jneurosci.2860-04.2004","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/15590928","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6730264","host_type":"repository"}],"fields_of_study":["Alzheimer's disease research and treatments","Parkinson's Disease Mechanisms and Treatments","Aluminum toxicity and tolerance in plants and animals"],"mesh_terms":["Aged","Aged, 80 and over","Alzheimer Disease","Animals","Brain","Cells, Cultured","Diabetes Mellitus","Female","Hippocampus","Humans","Insulin","Insulysin","Male","Mice, Transgenic","Middle Aged","Neurons","Receptor, Insulin","Safflower Oil","Signal Transduction","Up-Regulation","Amyloid beta-Peptides","Rats, Sprague-Dawley","Phosphatidylinositol 3-Kinases","Mice","Rats"],"keywords":["Insulin receptor","Insulin-degrading enzyme","Insulin","Disease","Receptor","Downstream (manufacturing)","Cascade","Insulin receptor substrate","Signal transduction","Neuroscience","Biology","Cell biology","Endocrinology","Internal medicine","Medicine","Chemistry","Insulin resistance"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"gen"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T19:46:33.962409Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}